Company Filing History:
Years Active: 2019
Title: Laila Ziko: Innovator in Nanoparticle-Based Cancer Therapy
Introduction
Laila Ziko is a prominent inventor based in Cairo, Egypt. She has made significant contributions to the field of cancer therapy through her innovative research. Her work focuses on developing advanced therapeutic methods that enhance the efficacy of existing treatments.
Latest Patents
Laila Ziko holds a patent for a nanoparticle-based combinatorial therapy. This invention provides a nano-particle based structure or composition for combinational cancer therapy. The structure features doxorubicin (DOX) physically loaded on core-shell silver polymeric nanoparticles (AgN-Ps) with a specific ratio of 3.3-5.5% doxorubicin to 1% silver to 2-10% polymer. This innovative structure enhances the cellular uptake of DOX compared to conventional combination therapies. The DOX-loaded nanoparticles improve the therapeutic efficiency of DOX while reducing its toxicity, which is not achievable when simply adding DOX and AgNPs.
Career Highlights
Laila Ziko is affiliated with The American University in Cairo, where she conducts her research and development work. Her dedication to advancing cancer treatment through innovative solutions has positioned her as a key figure in her field.
Collaborations
Laila collaborates with notable colleagues, including Nancy Mohamed Elbaz and Wael Mamdouh Sayed Sayed Ahmed. These partnerships enhance her research efforts and contribute to the development of effective cancer therapies.
Conclusion
Laila Ziko's work in nanoparticle-based combinatorial therapy represents a significant advancement in cancer treatment. Her innovative approach not only improves therapeutic efficiency but also reduces toxicity, showcasing her commitment to enhancing patient care.